Alkermes (ALKS)
NASDAQ: ALKS
· Real-Time Price · USD
29.36
-0.69 (-2.30%)
At close: May 23, 2025, 3:59 PM
28.64
-2.45%
After-hours: May 23, 2025, 05:00 PM EDT
-2.30% (1D)
| Bid | 25.33 |
| Market Cap | 4.84B |
| Revenue (ttm) | 1.51B |
| Net Income (ttm) | 352.71M |
| EPS (ttm) | 2.1 |
| PE Ratio (ttm) | 13.98 |
| Forward PE | 17.38 |
| Analyst | Buy |
| Ask | 34 |
| Volume | 1,551,000 |
| Avg. Volume (20D) | 1,724,363 |
| Open | 29.64 |
| Previous Close | 30.05 |
| Day's Range | 29.30 - 29.94 |
| 52-Week Range | 22.90 - 36.45 |
| Beta | 0.47 |
About ALKS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ALKS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ALKS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
+6.29%
Alkermes shares are trading higher after the compa...
Unlock content with
Pro Subscription
10 months ago
+6.04%
Alkermes shares are trading higher after the company reported better-than-expected Q2 financial results.
3 weeks ago · seekingalpha.com
Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial PossibleThe company's drug LYBALVI, approved for adults with Schizophrenia and bipolar I disorder, shows potential for label expansion to include pediatric patients to potentially boost revenue growth. The on...
